Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 25 clinical trials
Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-101 in Participants With Myotonic Dystrophy Type 1 (ACHIEVE)

The primary purpose of the study is to evaluate the safety and tolerability of multiple intravenous (IV) doses of DYNE-101 administered to participants with Myotonic Dystrophy Type 1 (DM1).

  • 0 views
  • 07 Oct, 2022
  • 1 location
Technology Assisted Rehabilitation for Upper Limb Function in Myotonic Dystrophy Type 1 (Technorehab)

Myotonic Dystrophy type 1 (DM1) is a genetic multisystem disease causing muscle weakness and myotonia. As a result, upper limb function might become impaired. There are little research regarding

  • 0 views
  • 13 Oct, 2022
Efficacy and Safety of Tideglusib in Congenital Myotonic Dystrophy

This is a randomized, multicenter, double-blind, placebo-controlled, Phase 2/3 study of patients (aged 6 to 16 years) diagnosed with Congenital Myotonic Dystrophy (Congenital DM1).

myotonic dystrophy
weakness
  • 10 views
  • 04 Oct, 2022
  • 12 locations
Venous Thromboembolism in Myotonic Dystrophy Type 1 (DM1-VTE)

Investigators identified a high risk of deep vein thrombosis and pulmonary embolism in patients presenting myotonic dystrophy type 1 treated in our hospital, 10 times higher than general

pulmonary embolism
myotonic dystrophy
Accepts healthy volunteers
monocytes
thromboembolic events
  • 25 views
  • 28 Feb, 2022
Effects of a 12-week Strength Training Program in Women With Myotonic Dystrophy Type 1

20 women with myotonic dystrophy type 1 (DM1) will complete a 12-week lower-limb strength training program. The training program consist of 3 series of 6 to 8 maximal repetitions of 5 different

myotonic dystrophy
  • 0 views
  • 20 Jun, 2022
  • 1 location
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Pitolisant on Excessive Daytime Sleepiness and Other Non-Muscular Symptoms in Patients With Myotonic Dystrophy Type 1, Followed by an Open-Label Extension

The primary objective of this study is to evaluate the safety and efficacy of pitolisant compared with placebo in treating excessive daytime sleepiness (EDS) in patients with Myotonic Dystrophy

myotonic dystrophy
drug test
respiratory assessment
  • 0 views
  • 14 Oct, 2022
  • 17 locations
Open Label Study in Adolescents and Children With Myotonic Disorders

This is an open-label, multi-centre, single arm, interventional study to describe the steady-state PK, safety, and efficacy of mexiletine in paediatric patients (6 to <18 years of age) with myotonic disorders.

respiratory assessment
  • 0 views
  • 27 Sep, 2021
Impact of P53 and SIRT1 in Type 2 Diabetes

Investigating the impact of p53 and SIRT1 in the development of type 2 DM

type 2 diabetes mellitus
metformin
  • 7 views
  • 03 Feb, 2022
  • 1 location
Clinical Study Evaluating Vildagliptin Versus Vildagliptin/Metformin on NAFLD With DM

Clinical study evaluating vildagliptin versus vildagliptin/metformin on NAFLD with DM.

metformin
  • 17 views
  • 04 Feb, 2022
  • 1 location
Best Available Therapy Versus Autologous Hematopoetic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS) (BEAT-MS)

This is a multi-center prospective rater-masked (blinded) randomized controlled trial of 156 participants, comparing the treatment strategy of Autologous Hematopoietic Stem Cell Transplantation (AHSCT) to the treatment strategy of Best Available Therapy (BAT) for treatment-resistant relapsing multiple sclerosis (MS). Participants will be randomized at a 1 to 1 (1:1) ratio. …

daclizumab
alemtuzumab
cyclophosphamide
active treatment
aubagio
  • 418 views
  • 04 Oct, 2022
  • 16 locations